SCHEMBL29844145

SCHEMBL29844145

COC(=O)C1CCC(n2ccc(Cl)c(C=O)c2=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ PKM P14618 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ ALDH1A1 P00352 5/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NSD2 O96028 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27186133 0.84 DUSP3 (0.44) MEN1KMT2ALMNAALDH1A1RAB9A
SCHEMBL27186129 0.84 DUSP3 (0.44) MEN1KMT2ALMNAALDH1A1RAB9A
SCHEMBL27186106 0.74 DHODH (0.36) SMN1; SMN2MEN1KMT2ALMNAALDH1A1
SCHEMBL27186227 0.73 MEN1 (0.38) SMN1; SMN2MEN1KMT2APKMLMNA
SCHEMBL32677973 0.70 ALDH1A1 (0.51) SMN1; SMN2MEN1KMT2APKMSLC6A4
SCHEMBL32677974 0.70 ALDH1A1 (0.51) SMN1; SMN2MEN1KMT2APKMSLC6A4
SCHEMBL25379016 0.70 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2APKMLMNA
SCHEMBL30442517 0.70 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2APKMLMNA
SCHEMBL29168362 0.70 MAP4K1 (0.38) SMN1; SMN2MEN1KMT2APKMALDH1A1
SCHEMBL29168368 0.69 P2RX7 (0.36) MEN1KMT2ALMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117651701-A Novel substituted bicyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-03-05 — — CN disclosed
WO-2022187266-A1 NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 SMN1; SMN2 1414/4885MEN1 688/4885KMT2A 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback